Primary Hepatocytes Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå¿¡ °üÇÑ Á¾ÇÕ º¸°í¼¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤µ¿Ç⡤±âȸ¡¤ÃËÁø¿äÀΡ¤°úÁ¦µîÀÇ Áß¿äÇÑ ½ÃÀå ¿ªÇÐÀ» öÀúÇÏ°Ô Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â ¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀåÀÇ 2025-2032³â ¿¹Ãø ¼ºÀå ±Ëµµ¸¦ ¼³¸íÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
ÃÊ´ë °£¼¼Æ÷ ½ÃÀå ±Ô¸ð(2025³â) : 2¾ï 7,290¸¸ ´Þ·¯
¿¹Ãø ½ÃÀå°¡Ä¡(2032³â) : 4¾ï 2,820¸¸ ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2025-2032³â) : 6.6%
ÃÊ´ë °£¼¼Æ÷ ½ÃÀå - ¸®Æ÷Æ® ¹üÀ§ :
°£¼¼Æ÷´Â Á¦¾à¿¬±¸, µ¶¼º½ÃÇè, ¾à¹°°³¹ß¿¡ ÇʼöÀûÀÎ Åø·Î ÀÛ¿ëÇϴ Ư¼ö °£¼¼Æ÷ÀÔ´Ï´Ù. ÀÌ ¼¼Æ÷µéÀº ½Å¾à°³¹ß, °£µ¶¼º ½ÃÇè, °£ÁúȯÀÇ in-vitro ¸ðµ¨ µî¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. 1Â÷ °£¼¼Æ÷ ½ÃÀåÀº ¿¬±¸±â°ü, Á¦¾àȸ»ç, ÀǾàǰ °³¹ß¾÷¹«¼öʱâ°ü(CRO)¿¡ ´ëÀÀÇϰí ÀÖÀ¸¸ç, Àΰ£ 1Â÷ °£¼¼Æ÷, Áã °£¼¼Æ÷, ºÒ¸êÈ °£¼¼Æ÷ µî ´Ù¾çÇÑ °£¼¼Æ÷ Á¦Ç°À» °ø±ÞÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¼¼Æ÷¹è¾ç ±â¼úÀÇ ¹ßÀü, º¸´Ù Á¤È®ÇÑ ¾à¹° °Ë»ç ¸ðµ¨¿¡ ´ëÇÑ ´ÏÁî Áõ°¡ÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
¼¼°è °£¼¼Æ÷ ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½Å¾à °³¹ß ¹× µ¶¼º Å×½ºÆ®¿¡¼ ½Å·ÚÇÒ ¼ö Àִ ü¿Ü ½ÃÇè ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °£¼¼Æ÷´Â °£ ±â´É Æò°¡, ÈÇÕ¹° ´ë»ç, °£ Áúȯ ¿¬±¸¿¡ ¸Å¿ì Áß¿äÇϸç, ÀǾàǰ ¿¬±¸°³¹ß¿¡ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÷´Ü °£¼¼Æ÷ ºÐ¸® ±â¼ú ¹× °³¼±µÈ ¼¼Æ÷¹è¾ç ½Ã½ºÅÛ °³¹ß°ú °°Àº ±â¼ú ¹ßÀüÀº °£¼¼Æ÷ÀÇ ¼º´É°ú À¯¿ë¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñµ¿¹° ½ÇÇè¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í °£ °ü·Ã Áúȯ Áõ°¡´Â ÀÇÇÐ ¿¬±¸ ºÐ¾ß¿¡¼ 1Â÷ °£¼¼Æ÷ÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:
À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí 1Â÷ °£¼¼Æ÷ ½ÃÀåÀº 1Â÷ °£¼¼Æ÷ ºÐ¸® ¹è¾ç ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ë¿¡ ´ëÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú¿¡´Â Àü¹® Àåºñ¿Í ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇϸç, ¼Ò±Ô¸ð ¿¬±¸¼Ò³ª ¿¹»êÀÌ ÇÑÁ¤µÈ ±â°ü¿¡¼´Â 1Â÷ °£¼¼Æ÷ÀÇ È°¿ëÀÌ Á¦ÇÑÀûÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àΰ£ °£Á¶Á÷°ø±ÞÀÌ Á¦ÇѵǾî ÀÖ°í, °£¼¼Æ÷ Á¶´Þ°ú °ü·ÃµÈ À±¸®Àû ¹®Á¦°¡ ½ÃÀå ¼ºÀå¿¡ Å« À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú Á¦¾à ¿¬±¸¿¡¼ÀÇ ¾ö°ÝÇÑ °¡À̵å¶óÀÎ Áؼö¿¡ ´ëÇÑ Çʿ伺Àº ½Å±Ô ÁøÃâ±â¾÷¿¡°Ô ½ÃÀå ÁøÀÔÀ» ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
¼¼Æ÷¹è¾ç ±â¼úÀÇ Çõ½Å, °£ Áúȯ ¿¬±¸ÀÇ ¹ßÀü, ´ëü ¾à¹° ½ÃÇè ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °£¼¼Æ÷ ½ÃÀåÀº Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. °£°æº¯Áõ, °£¿° µî ¸¸¼º °£Áúȯ Áõ°¡¿Í ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ Ã¤Åà Ȯ´ë·Î ½ÃÀå ±â¾÷Àº °£¼¼Æ÷¸¦ ±â¹ÝÀ¸·Î º¸´Ù È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¼ö´ÜÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦¾à»ç, CRO, ¿¬±¸±â°ü °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í ÇÔ²² »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇÏ°í ½ÃÀå¿¡¼ÀÇ ¸®´õ½ÊÀ» À¯ÁöÇϱâ À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
Àü ¼¼°è °£¼¼Æ÷ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
´Ù¾çÇÑ ¿¬±¸ ȯ°æ¿¡¼ ¾î¶² °£¼¼Æ÷ À¯Çü°ú ¿ëµµ°¡ 1Â÷ °£¼¼Æ÷ ¼ö¿ä¸¦ ÁÖµµÇϰí Àִ°¡?
±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô °£¼¼Æ÷ ½ÃÀå °æÀï ±¸µµ¸¦ ¹Ù²Ù°í Àִ°¡?
Ãʱ⠰£¼¼Æ÷ ½ÃÀå¿¡ ±â¿©Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷Àº ¾îµðÀ̸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è 1Â÷ °£¼¼Æ÷ ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ ÇコÄɾî ÁöÃâ Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
±ÔÁ¦ »óȲ
Á¦Ç° äÅà ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
ÁÖ¿ä °Å·¡¿Í ÇÕº´
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ëÀû ¸ÅÃâ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025-2032³â
¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á : Á¦Ç°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Á¦Ç°º°, 2019-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Á¦Ç°º°, 2025-2032³â
µ¿°á º¸Á¸µÈ ºÎÀ¯ °£¼¼Æ÷
½Å¼± ÇöŹ¾× °£¼¼Æ÷
3D(½ºÆä·ÎÀ̵å) °£¼¼Æ÷
Áõ½Ä °£¼¼Æ÷(¹è¾ç °¡´É)
¹ÌÇØ¼® °£¼¼Æ÷
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç°
¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á : Á¾
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
2019-2024³â¿¡¼ À¯Çüº° ½ÃÀå ±Ô¸ðÀÇ °ú°Å ºÐ¼®
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, À¯Çüº°, 2025-2032³â
Àΰ£
Áã
¸¶¿ì½º
°³
¿ø¼þÀÌ
¸»
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¾
¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á : ¾ÖÇø®ÄÉÀ̼Ç/¾î¼¼ÀÌ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ¾ÖÇø®ÄÉÀ̼Ç/¾î¼¼À̺°, 2019-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ¾ÖÇø®ÄÉÀ̼Ç/¾î¼¼À̺°, 2025-2032³â
¼¼Æ÷ »ýÁ¸·ü ¾î¼¼ÀÌ
½ÃÅäÅ©·Ò È¿¼Ò Ȱ¼º
°í³óµµ ¼¼Æ÷ µ¶¼º
Æ®·£½ºÆ÷ÅÍ ÀúÇØ ¾î¼¼ÀÌ
ü¿Ü °íÀ¯ Ŭ¸®¾î·±½º
ÀÎÁöÁú ¾î¼¼ÀÌ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¾ÖÇø®ÄÉÀ̼Ç/¾î¼¼ÀÌ
¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2025-2032³â
¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Çмú Á¶»ç±â°ü
°è¾à Á¶»ç±â°ü
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ
Á¦5Àå ¼¼°èÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
2019-2024³â Áö¿ªº° ½ÃÀå ±Ô¸ðÀÇ ¿ª»ç ¸ñÇ¥ ºÐ¼®
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025-2032³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦7Àå À¯·´ÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÃÊ´ë °£¼¼Æ÷ ½ÃÀå Àü¸Á :
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀï °ÝÈ ¸Ê
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼-°³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Thermo Fisher Scientific Inc.
Merck KGaA
Lonza
Takara Bio Inc.
American Type Culture Collection(ATCC)
Corning Inc.
Cell Biologics, Inc.
Creative Bioarray
Axol Bioscience Ltd.
HiMedia Laboratories
NEXEL Co., Ltd.
AnaBios
Cytes Biotechnologies SL
ZenBio, Inc.(BioIVT)
iXCells Biotechnologies
ScienCell Research Laboratories, Inc.
Kerafast
Kosheeka
XenoTech
LifeNet Health LifeSciences
Cell Guidance Systems LLC
Applied Biological Materials Inc.(abm)
Discovery Life Sciences
Innoprot
Novabiosis
Á¦13Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»çÀÇ ÀüÁ¦
µÎÀÚ¾î¿Í ¾à¾î
KSA
Persistence Market Research has recently released a comprehensive report on the worldwide market for primary hepatocytes. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global primary hepatocytes market from 2025 to 2032.
Key Insights:
Primary Hepatocytes Market Size (2025E): US$ 272.9 Mn
Projected Market Value (2032F): US$ 428.2 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 6.6%
Primary Hepatocytes Market - Report Scope:
Primary hepatocytes are specialized liver cells that serve as essential tools for pharmaceutical research, toxicity testing, and drug development. These cells are widely used in drug discovery, hepatotoxicity testing, and in-vitro models for liver diseases. The primary hepatocytes market caters to research institutions, pharmaceutical companies, and contract research organizations (CROs), offering a variety of hepatocyte products, including human primary hepatocytes, rat hepatocytes, and immortalized hepatocytes. Market growth is driven by increasing demand for personalized medicine, advancements in cell culture technology, and the rising need for more accurate drug testing models.
Market Growth Drivers:
The global primary hepatocytes market is propelled by several key factors, including the growing demand for personalized medicine and the rising need for reliable in-vitro testing models in drug discovery and toxicity testing. Hepatocytes are crucial in assessing liver function, metabolizing compounds, and studying liver diseases, leading to their widespread adoption in pharmaceutical R&D. Technological advancements, such as the development of advanced hepatocyte isolation techniques and improved cell culture systems, have enhanced the performance and utility of primary hepatocytes, further boosting market expansion. Moreover, the growing focus on non-animal testing methods and the increasing number of liver-related diseases contribute to the rising adoption of primary hepatocytes in medical research.
Market Restraints:
Despite promising growth prospects, the primary hepatocytes market faces challenges related to the high cost of primary hepatocyte isolation and culture systems. These techniques require specialized equipment and skilled personnel, which can limit the accessibility of primary hepatocytes to smaller laboratories or institutions with limited budgets. Additionally, the limited supply of human liver tissue and ethical concerns associated with sourcing hepatocytes can pose significant barriers to market growth. Regulatory hurdles and the need for compliance with stringent guidelines in pharmaceutical research further complicate market entry for new players.
Market Opportunities:
The primary hepatocytes market presents significant growth opportunities driven by innovations in cell culture technology, advancements in liver disease research, and increasing demand for alternative drug testing models. The rise in chronic liver diseases such as cirrhosis and hepatitis, along with the growing adoption of personalized medicine approaches, provides new avenues for market players to develop more effective hepatocyte-based solutions. Strategic partnerships between pharmaceutical companies, CROs, and research institutions, alongside investments in R&D, are crucial to capitalize on emerging opportunities and sustain market leadership.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the primary hepatocytes market globally?
Which hepatocyte types and applications are driving the demand for primary hepatocytes across different research settings?
How are technological advancements reshaping the competitive landscape of the primary hepatocytes market?
Who are the key players contributing to the primary hepatocytes market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global primary hepatocytes market?
Competitive Intelligence and Business Strategy:
Leading players in the global primary hepatocytes market, including Thermo Fisher Scientific, Lonza Group, and Merck KGaA, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced hepatocyte culture systems, liver-on-a-chip models, and improved hepatocyte isolation techniques, catering to diverse research needs. Collaborations with pharmaceutical companies, biotechnology firms, and academic research institutions facilitate market access and promote the development of more effective hepatocyte-based solutions. Moreover, emphasis on clinical research, drug development, and regulatory compliance fosters market growth and enhances product offerings in the evolving hepatocyte market.
Key Companies Profiled:
Thermo Fisher Scientific
Lonza Group
Merck KGaA
Sigma-Aldrich (now part of Merck)
BioIVT
CellzDirect (a part of Thermo Fisher)
In Vitro Technologies
Primorigen Biosciences
PharmaCyte Biotech
Wuxi AppTec
Global Primary Hepatocytes Market Segmentation
By Product
Cryopreserved Suspension Hepatocytes
Fresh Suspension Hepatocytes
3D (Spheroid) Hepatocytes
Expanded Hepatocytes (Plateable)
Non-characterized Hepatocytes
By Species
Human
Rat
Mouse
Dog
Monkey
Horse
By Application/Assay
Cell Viability Assay
Cytochrome Enzyme Activity
High Content Cytotoxicity
Transporter Inhibition Assay
In Vitro Intrinsic Clearance
Phospholipids Assay
By End User
Biopharmaceutical companies
Academic and Research institutes
Contract Research Organizations
By Region
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Primary Hepatocytes Market Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis
4. Global Primary Hepatocytes Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Primary Hepatocytes Market Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
4.3.3.1. Cryopreserved Suspension Hepatocytes
4.3.3.2. Fresh Suspension Hepatocytes
4.3.3.3. 3D (Spheroid) Hepatocytes
4.3.3.4. Expanded Hepatocytes (Plateable)
4.3.3.5. Non-characterized Hepatocytes
4.3.4. Market Attractiveness Analysis: Product
4.4. Global Primary Hepatocytes Market Outlook: Species
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By Species, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
4.4.3.1. Human
4.4.3.2. Rat
4.4.3.3. Mouse
4.4.3.4. Dog
4.4.3.5. Monkey
4.4.3.6. Horse
4.4.3.7. Others
4.4.4. Market Attractiveness Analysis: Species
4.5. Global Primary Hepatocytes Market Outlook: Application/Assay
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Application/Assay, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
4.5.3.1. Cell Viability Assay
4.5.3.2. Cytochrome Enzyme Activity
4.5.3.3. High Content Cytotoxicity
4.5.3.4. Transporter Inhibition Assay
4.5.3.5. In Vitro Intrinsic Clearance
4.5.3.6. Phospholipids Assay
4.5.3.7. Others
4.5.4. Market Attractiveness Analysis: Application/Assay
4.6. Global Primary Hepatocytes Market Outlook: End User
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
4.6.3.1. Biopharmaceutical companies
4.6.3.2. Academic and Research institutes
4.6.3.3. Contract Research Organizations
4.6.4. Market Attractiveness Analysis: End User
5. Global Primary Hepatocytes Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Primary Hepatocytes Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Product
6.2.3. By Species
6.2.4. By Application/Assay
6.2.5. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
6.4.1. Cryopreserved Suspension Hepatocytes
6.4.2. Fresh Suspension Hepatocytes
6.4.3. 3D (Spheroid) Hepatocytes
6.4.4. Expanded Hepatocytes (Plateable)
6.4.5. Non-characterized Hepatocytes
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
6.5.1. Human
6.5.2. Rat
6.5.3. Mouse
6.5.4. Dog
6.5.5. Monkey
6.5.6. Horse
6.5.7. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
6.6.1. Cell Viability Assay
6.6.2. Cytochrome Enzyme Activity
6.6.3. High Content Cytotoxicity
6.6.4. Transporter Inhibition Assay
6.6.5. In Vitro Intrinsic Clearance
6.6.6. Phospholipids Assay
6.6.7. Others
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
6.7.1. Biopharmaceutical companies
6.7.2. Academic and Research institutes
6.7.3. Contract Research Organizations
6.8. Market Attractiveness Analysis
7. Europe Primary Hepatocytes Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product
7.2.3. By Species
7.2.4. By Application/Assay
7.2.5. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
7.4.1. Cryopreserved Suspension Hepatocytes
7.4.2. Fresh Suspension Hepatocytes
7.4.3. 3D (Spheroid) Hepatocytes
7.4.4. Expanded Hepatocytes (Plateable)
7.4.5. Non-characterized Hepatocytes
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
7.5.1. Human
7.5.2. Rat
7.5.3. Mouse
7.5.4. Dog
7.5.5. Monkey
7.5.6. Horse
7.5.7. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
7.6.1. Cell Viability Assay
7.6.2. Cytochrome Enzyme Activity
7.6.3. High Content Cytotoxicity
7.6.4. Transporter Inhibition Assay
7.6.5. In Vitro Intrinsic Clearance
7.6.6. Phospholipids Assay
7.6.7. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
7.7.1. Biopharmaceutical companies
7.7.2. Academic and Research institutes
7.7.3. Contract Research Organizations
7.8. Market Attractiveness Analysis
8. East Asia Primary Hepatocytes Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product
8.2.3. By Species
8.2.4. By Application/Assay
8.2.5. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
8.4.1. Cryopreserved Suspension Hepatocytes
8.4.2. Fresh Suspension Hepatocytes
8.4.3. 3D (Spheroid) Hepatocytes
8.4.4. Expanded Hepatocytes (Plateable)
8.4.5. Non-characterized Hepatocytes
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
8.5.1. Human
8.5.2. Rat
8.5.3. Mouse
8.5.4. Dog
8.5.5. Monkey
8.5.6. Horse
8.5.7. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
8.6.1. Cell Viability Assay
8.6.2. Cytochrome Enzyme Activity
8.6.3. High Content Cytotoxicity
8.6.4. Transporter Inhibition Assay
8.6.5. In Vitro Intrinsic Clearance
8.6.6. Phospholipids Assay
8.6.7. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
8.7.1. Biopharmaceutical companies
8.7.2. Academic and Research institutes
8.7.3. Contract Research Organizations
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Primary Hepatocytes Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product
9.2.3. By Species
9.2.4. By Application/Assay
9.2.5. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
9.4.1. Cryopreserved Suspension Hepatocytes
9.4.2. Fresh Suspension Hepatocytes
9.4.3. 3D (Spheroid) Hepatocytes
9.4.4. Expanded Hepatocytes (Plateable)
9.4.5. Non-characterized Hepatocytes
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
9.5.1. Human
9.5.2. Rat
9.5.3. Mouse
9.5.4. Dog
9.5.5. Monkey
9.5.6. Horse
9.5.7. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
9.6.1. Cell Viability Assay
9.6.2. Cytochrome Enzyme Activity
9.6.3. High Content Cytotoxicity
9.6.4. Transporter Inhibition Assay
9.6.5. In Vitro Intrinsic Clearance
9.6.6. Phospholipids Assay
9.6.7. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
9.7.1. Biopharmaceutical companies
9.7.2. Academic and Research institutes
9.7.3. Contract Research Organizations
9.8. Market Attractiveness Analysis
10. Latin America Primary Hepatocytes Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product
10.2.3. By Species
10.2.4. By Application/Assay
10.2.5. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
10.4.1. Cryopreserved Suspension Hepatocytes
10.4.2. Fresh Suspension Hepatocytes
10.4.3. 3D (Spheroid) Hepatocytes
10.4.4. Expanded Hepatocytes (Plateable)
10.4.5. Non-characterized Hepatocytes
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
10.5.1. Human
10.5.2. Rat
10.5.3. Mouse
10.5.4. Dog
10.5.5. Monkey
10.5.6. Horse
10.5.7. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
10.6.1. Cell Viability Assay
10.6.2. Cytochrome Enzyme Activity
10.6.3. High Content Cytotoxicity
10.6.4. Transporter Inhibition Assay
10.6.5. In Vitro Intrinsic Clearance
10.6.6. Phospholipids Assay
10.6.7. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
10.7.1. Biopharmaceutical companies
10.7.2. Academic and Research institutes
10.7.3. Contract Research Organizations
10.8. Market Attractiveness Analysis
11. Middle East & Africa Primary Hepatocytes Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product
11.2.3. By Species
11.2.4. By Application/Assay
11.2.5. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
11.4.1. Cryopreserved Suspension Hepatocytes
11.4.2. Fresh Suspension Hepatocytes
11.4.3. 3D (Spheroid) Hepatocytes
11.4.4. Expanded Hepatocytes (Plateable)
11.4.5. Non-characterized Hepatocytes
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
11.5.1. Human
11.5.2. Rat
11.5.3. Mouse
11.5.4. Dog
11.5.5. Monkey
11.5.6. Horse
11.5.7. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
11.6.1. Cell Viability Assay
11.6.2. Cytochrome Enzyme Activity
11.6.3. High Content Cytotoxicity
11.6.4. Transporter Inhibition Assay
11.6.5. In Vitro Intrinsic Clearance
11.6.6. Phospholipids Assay
11.6.7. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
11.7.1. Biopharmaceutical companies
11.7.2. Academic and Research institutes
11.7.3. Contract Research Organizations
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Thermo Fisher Scientific Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Merck KGaA
12.3.3. Lonza
12.3.4. Takara Bio Inc.
12.3.5. American Type Culture Collection (ATCC)
12.3.6. Corning Inc.
12.3.7. Cell Biologics, Inc.
12.3.8. Creative Bioarray
12.3.9. Axol Bioscience Ltd.
12.3.10. HiMedia Laboratories
12.3.11. NEXEL Co., Ltd.
12.3.12. AnaBios
12.3.13. Cytes Biotechnologies S.L.
12.3.14. ZenBio, Inc. (BioIVT)
12.3.15. iXCells Biotechnologies
12.3.16. ScienCell Research Laboratories, Inc.
12.3.17. Kerafast
12.3.18. Kosheeka
12.3.19. XenoTech
12.3.20. LifeNet Health LifeSciences
12.3.21. Cell Guidance Systems LLC
12.3.22. Applied Biological Materials Inc. (abm)
12.3.23. Discovery Life Sciences
12.3.24. Innoprot
12.3.25. Novabiosis
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations